Research
Molecular
The FDA-approved label for resmetirom does not require liver biopsy to confirm the diagnosis of fibrotic MASH.
Clinicians can diagnose fibrotic MASH without the need for invasive liver biopsy, simplifying patient assessment.
StrongSupportsmedium confidence
Notably, the FDA-approved label does not require liver biopsy to confirm the diagnosis of fibrotic MASH.
Why this rating
Based on official FDA documentation.
Source
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Vincent Chen et al. · Hepatology · 2024
DOI 10.1097/hep.0000000000001112
otherCited 145×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →